United States - English - NLM (National Library of Medicine)

llc federal solutions - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 100 mg in 1 ml - indication and usage levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. contraindications this product should not be administered to patients who have previously exhibited hypersensitivity to levetiracetam or any of the inactive ingredients in levetiracetam oral solution. drug abuse and dependence the abuse and dependence potential of levetiracetam has not been evaluated in human studies.

United States - English - NLM (National Library of Medicine)

llc federal solutions - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate 1.2 mg in 1 ml - indication chlorhexidine gluconate oral rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. chlorhexidine gluconate oral rinse has not been tested among patients with acute necrotizing ulcerative gingivitis (anug). for patients having coexisting gingivitis and periodontitis, see precautions. contraindications chlorhexidine gluconate oral rinse should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients. pediatric use clinical effectiveness and safety of chlorhexidine gluconate oral rinse have not been established in children under the age of 18.

United States - English - NLM (National Library of Medicine)

llc federal solutions - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 20 mg in 1 ml - indications and usage lidocaine hydrochloride oral topical solution, usp (viscous) 2% is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. it is also useful for reducing gagging during the taking of x-ray pictures and dental impressions. contraindications lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type, or to other components of the solution. pediatric use dosages in children should be reduced, commensurate with age, body weight and physical condition. (see dosage and administration).

United States - English - NLM (National Library of Medicine)

3t federal solutions llc - salsalate (unii: v9mo595c9i) (salsalate - unii:v9mo595c9i) - salsalate 500 mg - carefully consider the potential benefits and risks of salsalate tablets, usp and other treatment options before deciding to use salsalate tablets, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. salsalate tablet, usp is contraindicated in patients with known hypersensitivity to salsalate. salsalate tablet, usp should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings - anaphylactoid reactions , and precautions - preexisting asthma ). salsalate tablet, usp is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see warnings ). drug abuse and depend

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; purified talc; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; hyprolose; iron oxide red; macrogol 400 - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule, hard - excipient ingredients: povidone; titanium dioxide; iron oxide yellow; iron oxide red; croscarmellose sodium; gelatin; pregelatinised maize starch; indigo carmine; magnesium stearate - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

United States - English - NLM (National Library of Medicine)

llc federal solutions - sennosides a and b (unii: 1b5fpi42en) (sennosides a and b - unii:1b5fpi42en) - sennosides a and b 8.8 mg in 5 ml - purpose laxative uses relieves occasional constipation (irregularity), generally produces bowel movement in 6-12 hours stop use and ask a doctor if you have rectal bleeding or fail to have bowel movement after use of laxative. these may indicate a serious condition.

United States - English - NLM (National Library of Medicine)

llc federal solutions - guaifenesin (unii: 495w7451vq) (guaifenesin - unii:495w7451vq), dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots) - guaifenesin 100 mg in 5 ml - purpose of guaifenesin: expectorant purpose of dextromethorphan hbr: cough suppressant uses - temporarily relieves cough due to minor throat and bronchial irritation - helps loosen phlegm (mucus) - thin bronchial secretions to make coughs more productive stop use and ask a doctor if - cough lasts more than 7 days or occurs with fever, rash, or headaches that lasts. this could be signs of a serious condition - hypersensitive to any ingredients

United States - English - NLM (National Library of Medicine)

llc federal solutions - docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag) - docusate sodium 50 mg in 5 ml - purpose stool softener laxative use - for relief of  occasional constipation - generally produces bowel movement in 12-72 hours do not use - if you are presently taking mineral oil - when abdominal pain, nausea, or vomiting are present - for longer than one week stop use and ask a doctor if - you have rectal bleeding - you fail to have a bowel movement after use of this product these may indicate a serious condition.

United States - English - NLM (National Library of Medicine)

llc federal solutions - aluminum hydroxide (unii: 5qb0t2iun0) (aluminum hydroxide - unii:5qb0t2iun0) - aluminum hydroxide 320 mg in 5 ml - purpose antacid uses for the relief of - heartburn - acid indigestion - sour stomach stop use and ask a doctor if symptoms last more than 2 weeks